This suggests that TNO155 has a dual role in inhibiting SHP2 in both cancer cells and immune cells (inhibits immunosuppressive macrophages), which could potentially enhance the effectiveness of immune checkpoint therapy. This evidence concerns the gene PTPN11 and cancer.